Globeflex Capital L P Purchases New Shares in AngioDynamics, Inc. $ANGO

Globeflex Capital L P bought a new position in AngioDynamics, Inc. (NASDAQ:ANGO) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 104,155 shares of the medical instruments supplier’s stock, valued at approximately $1,355,000.

Other institutional investors also recently modified their holdings of the company. Franklin Resources Inc. boosted its holdings in AngioDynamics by 2.3% in the fourth quarter. Franklin Resources Inc. now owns 48,359 shares of the medical instruments supplier’s stock worth $621,000 after acquiring an additional 1,076 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in AngioDynamics by 146.4% during the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 1,199 shares during the period. Deutsche Bank AG boosted its holdings in AngioDynamics by 5.9% in the fourth quarter. Deutsche Bank AG now owns 35,584 shares of the medical instruments supplier’s stock worth $457,000 after purchasing an additional 1,992 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new position in shares of AngioDynamics in the 4th quarter worth $27,000. Finally, Price T Rowe Associates Inc. MD boosted its position in AngioDynamics by 5.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 44,298 shares of the medical instruments supplier’s stock worth $569,000 after purchasing an additional 2,263 shares during the last quarter. 89.43% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ANGO. HC Wainwright lifted their price target on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Zacks Research lowered AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Canaccord Genuity Group lifted their target price on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a report on Friday, July 17th. Finally, Wall Street Zen upgraded AngioDynamics from a “hold” rating to a “buy” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, AngioDynamics currently has a consensus rating of “Hold” and a consensus price target of $19.50.

Insider Activity

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 23,370 shares of AngioDynamics stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the transaction, the senior vice president directly owned 64,745 shares of the company’s stock, valued at $953,046.40. The trade was a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.00% of the stock is owned by insiders.

AngioDynamics Stock Performance

ANGO stock opened at $15.77 on Tuesday. The company’s fifty day moving average price is $14.03 and its 200-day moving average price is $12.10. AngioDynamics, Inc. has a one year low of $9.39 and a one year high of $16.29. The company has a market capitalization of $651.81 million, a PE ratio of -18.13 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.04. The firm had revenue of $86.61 million for the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, research analysts predict that AngioDynamics, Inc. will post -0.25 EPS for the current fiscal year.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.